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Abstract We have isolated a 1785-bp complementary DNA
(cDNA) encoding the murine P2X7 receptor subunit from NTW8
mouse microglial cells. The encoded protein has 80% and 85%
homology to the human and rat P2X7 subunits, respectively.
Functional properties of the heterologously expressed murine
P2X7 homomeric receptor broadly resembled those of the P2X7
receptor in the native cell line. However, marked phenotypic
differences were observed between the mouse receptor, and the
other P2X7 receptor orthologues isolated with respect to agonist
and antagonist potencies, and the kinetics of formation of the
large aqueous pore.
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1. Introduction
P2X receptors are ligand-gated ion channels, which are ac-
tivated by extracellular ATP. Their activation results in the
opening of a non-selective cation channel with signi¢cant per-
meability to calcium [1,2]. In contrast to other P2X receptor
subunits (P2X1ÿ6 [3]), the operational behaviour of P2X7 is
unique. Upon brief activation by agonist, the homomeric re-
ceptor acts as a non-selective cation channel. However, re-
peated or prolonged application of higher agonist concentra-
tions, especially in solutions containing low concentrations of
extracellular divalent cations, creates a much larger aqueous
pore. Formation of this pore allows entry of £uorescent DNA
binding dyes such as YO-PRO-1 (629 Da) and eventually
leads to cell lysis. These same responses to ATP have been
shown for native P2 receptors expressed by mast cells, macro-
phages or microglia and these receptors were previously re-
ferred to as P2Z receptors [4]. cDNAs encoding the rat and
human P2X7 receptor subunits have recently been isolated
[1,2], and their pharmacological and electrophysiological
properties, when they assemble homomeric channels, charac-
terised. The characteristics of these P2X7 receptor orthologues
di¡er signi¢cantly from those of the P2X7 receptor expressed
endogenously in a mouse microglial cell line, NTW8 [5,6]. It
was unclear whether these di¡erences were conferred by spe-
cies variation in the receptor sequence, expression level, or
possible heteropolymerisation of the native P2X7 receptor
subunit with another subunit(s). Here we report isolation of
a cDNA encoding the murine P2X7 receptor from mouse
NTW8 microglial cells, and show that its functional properties
di¡er from rat and human P2X7 recombinant receptors, when
heterologously expressed in human embryonic kidney (HEK-
293) cells.
2. Materials and methods
2.1. Isolation of cDNA encoding the murine P2X7 receptor
The NTW8 mouse microglia cells were cultured to con£uency as
described [6]. Total RNA from these cells was extracted using a micro
RNA isolation kit (Stratagene, Cambridge, UK), and was treated with
RNase free DNase I (Stratagene) for 30 min at 37‡C. First strand
cDNA was synthesised (60 min, 42‡C) from 10 Wg of DNase treated
total RNA using oligo(dT)18 primer and Moloney murine leukemia
virus reverse transcriptase (First Strand Synthesis Kit, Clontech, Palo
Alto, CA, USA). A control reaction in the absence of reverse tran-
scriptase was also carried out. The sequence speci¢c primers based on
the recently published rat P2X7 cDNA sequence [1] were designed to
amplify the entire coding sequence of the murine orthologue of this
subunit in a polymerase chain reaction (PCR). The primers were as
follows: forward primer, 5P-ATGCCGGCTTGCTGCAGCTGGAA-
CGATGTCTTT-3P ; reverse primer, 5P-TCAGTAGGGATACTTGA-
AGCCACTGTACTGCCC-3P. PCR ampli¢cations were performed
on 2 Wl of ¢rst strand reaction using forward and reverse primers
(200 ng each), 200 WM of each deoxynucleotides, 1.5 mM MgCl2 in
the presence of 2.5 units of AmpliTaq Gold DNA polymerase (PA
Applied Biosystems, Warrington, UK). Cycling parameters were:
95‡C, 9 min for 1 cycle; 94‡C, 1 min, 57‡C, 1 min, 72‡C, 3 min for
35 cycles, with a ¢nal extension at 72‡C for 10 min. The PCR reac-
tions were then analysed by agarose gel electrophoresis. A single
product was isolated and cloned into pCR 2.1 vector (TA Cloning
kit, Invitrogen, Leek, The Netherlands) according to the manufactur-
er’s instructions. Ten clones were sequenced completely using an au-
tomated DNA sequencer. For functional expression of the receptor,
murine P2X7 cDNA was subcloned into pcDNA 3.1(3) mammalian
expression vector at the NotI-HindIII sites to give the correct orien-
tation for transcription. The identity and orientation of the resulting
clones were veri¢ed by sequencing.
2.2. Heterologous expression
1U106 wild-type HEK-293 cells, shown previously to be devoid of
expressed endogenous P2X receptors [1,7], were transfected with 5 Wg
murine P2X7 cDNA plasmid construct, using an electroporator (Easy-
Ject, EquiBio, Kent, UK). Transfected cells were then selected in
complete media (DMEM; Gibco-BRL, Paisley, UK) containing
10% foetal bovine serum (Gibco-BRL) and 500 Wg/ml geneticin sulfate
(G418; Gibco-BRL) for stable expression of the murine P2X7 recep-
tor, and passaged when con£uent using standard methods.
2.3. Electrophysiological recordings
Recordings from HEK-293 cells transfected with mouse, rat [1] or
human [2] P2X7 receptor cDNA were made essentially as described
[6]. Brie£y, cells were perfused with extracellular solution, consisting
of (in mM): NaCl 145, KCl 2, CaCl2 0.5, HEPES 10, D-glucose 10
(pH 7.3, osmolarity 300 mOsm), and whole cell patch-clamp record-
ings [8] were made with electrodes (resistance 2^5 M6) ¢lled with (in
mM): Cs aspartate 145, EGTA 11, HEPES 5, NaCl 2 (pH 7.3, osmo-
larity 290 mOsm). Currents were ¢ltered with a corner frequency of
1^5 kHz (8-pole Bessel ¢lter), digitised at 2^10 kHz using a Digidata
1200A (Axon Instruments, CA, USA) interface, and stored on com-
puter. Data was only obtained from cells with a residual series resist-
ance of less than 18 M6, and compensation for series resistance was
used (s 75%). Cells were voltage-clamped at 390 mV, unless other-
wise stated. For voltage-ramp experiments, reported voltages were
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corrected for the junction potential between the internal solution and
the extracellular solution in which zero current was obtained before
forming a seal. All experiments were performed at room temperature
(22^24‡C). Concentration-e¡ect curves to ATP and 2P- and 3P-O-
(4-benzoylbenzoyl)-adenosine 5P-triphosphate (BzATP; Sigma, Poole,
UK) were determined by application of agonists to naive cells for 2 s
using a computer controlled fast-£ow U-tube system [9]. EC50 values
were derived using a 3 parameter logistic equation (GraphPad Prism,
CA, USA). Current augmentation [6] was studied by repeated appli-
cation of 1 mM ATP (for 1 s every 20 s), up to 30 times. Current-
voltage relationships were determined by performing a voltage ramp,
over a 500-ms time course, from 375 to +60 mV holding potential, in
the absence and presence of 100 WM BzATP.
2.4. YO-PRO-1 uptake
Uptake of the DNA binding dye, YO-PRO-1 (Molecular Probes,
OR, USA) was performed essentially as described [10]. Con£uent
NTW8 or HEK-293 cells, stably expressing the recombinant murine,
rat [1] or human [2,7] P2X7 receptors were harvested, washed with ice-
cold phosphate bu¡ered saline (PBS) and centrifuged at 250Ug for
5 min. The supernatant was discarded and the cells washed once in
assay bu¡er consisting of (in mM): sucrose 280, HEPES 10, N-meth-
yl-D-glucamine (NMDG) 5, KCl 5.6, glucose 10, CaCl2 1 (pH 7.4).
YO-PRO-1 in£ux was initiated by the addition of 100 Wl of cell sus-
pension to 50 Wl YO-PRO-1 (1.4 WM) and agonist mixture in assay
bu¡er, and was performed in 96-well polystyrene 1/2 area £at bottom
plates (Costar, Bucks, UK) at 37‡C. The e¡ects of 1-(N,O-bis[5-iso-
quinolinesulfonyl]-N-methyl-L-tyrosyl)-4-phenylpiperazine (KN-62),
and pyridoxal-phosphate-6-azophenyl-2P,4P-disulfonic acid (PPADS)
were studied by pre-incubation of cells for 20^30 min prior to addi-
tion of YO-PRO-1 and agonist; the e¡ects of this agent were also
studied on HEK-293 cells expressing the human recombinant P2X7
receptor [7]. Reactions were terminated by centrifugation of the plates
at 200Ug for 5 min. Fluorescence was measured using a plate reader
(Canberra-Packard, FluoroCount, Berks, UK) with an emission wave-
length of 530 nm and an excitation wavelength of 485 nm.
3. Results
3.1. Isolation of the mouse P2X7 cDNA
RT-PCR performed on mouse microglial total RNA pro-
duced a single 1785-bp product using speci¢c primers based
on the rat P2X7 DNA sequence (Fig. 1). Sequencing revealed
a single open reading frame corresponding to a protein of 595
amino acids (Fig. 2). The encoded protein showed a high
degree of homology to the recently cloned human and rat
P2X7 subunits (80 and 85% identity, respectively), con¢rming
its identity as a species orthologue of this P2X subunit (Fig.
2). However, this identity is less than that found for species
orthologues of other P2X subunits (88^95% [11,12] and J.
Simon, unpublished observation). The divergence in the ami-
no acid sequence among the three species occurs predomi-
nantly in the extracellular loop and in the long C-terminal
tail region, suggesting that subtle di¡erences in the agonist
potency and the kinetics of the pore formation could be ex-
pected (Fig. 2).
3.2. Functional studies
In low divalent cation-containing solution, BzATP and
ATP evoked whole-cell inward currents (at a holding potential
of 390 mV) in all mouse P2X7-transfected HEK-293 cells
tested, with BzATP being more potent than ATP. Brief appli-
cations of agonists produced concentration-e¡ect curves with
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Fig. 1. Agarose gel electrophoresis of PCR ampli¢cation from cul-
tured NTW8 mouse microglia cells. The gel (1%) was stained with
ethidium bromide. Lane 1: 1-kb and lane 5: 100-bp DNA ladder
(Gibco-BRL); Lane 2: PCP ampli¢cation product obtained from
¢rst strand cDNA using the rat P2X7 speci¢c primers. The band
(1810 bp) corresponds to the predicted size of the mouse mP2X7
cDNA-coding region. Lanes 3 and 4 are control reactions per-
formed either in the absence of reverse transcriptase in the ¢rst
strand reaction (lane 3) or in the absence of DNA template during
the PCR ampli¢cation (lane 4). The PCR ampli¢cations were re-
peated at least 3 times from di¡erent RNA preparations.
Table 1
Pharmacological characteristics of native mouse P2X7 receptor (NTW8) in comparison to recombinant mP2X7, hP2X7, and rP2X7 receptors
mP2X7 NTW8 hP2X7 rP2X7
Electrophysiology
BzATP EC50 (WM) 90.4 (70.4^116.2) 58.3 (46.1^73.9) 52.4 (36.3^75.6) 2.2 (1.7^2.9)
ATP EC50 (WM) 734 (707^762) 298 (255^347) 779 (372^1631) 220 (142^234)
YO-PRO-1 uptake
BzATP EC50 (WM) 17.3 (14.8^20.2) 4.6 (4.1^5.3) 0.47 (0.67^0.59) 0.072 (0.062^0.083)
ATP EC50 (WM) 214 (176^259) 46.5 (40.3^53.7) ND ND
PPADS IC50 (WM) 9.0 (7.5^11.0) 7.0 (5.4^9.0) 0.015 (0.012^0.019) 0.087 (0.07^0 .11)
KN-62 IC50 (nM) 180 (120^253) 1170 (210^1120) 11 (8^18) s 3000a
Top two rows: EC50 data obtained from electrophysiological experiments, from cells voltage clamped at 390 mV. Rows 3 and 4: EC50 values
derived from YO-PRO-1 experiments. Rows 5 and 6: antagonist data obtained from YO-PRO-1 uptake experiments. Data is geometric mean with
95% con¢dence intervals, obtained from at least 6 determinations.
aSee [15].
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estimated EC50 values of 164.3 (89.3^302.2) WM and 1700
(900^3100) WM (BzATP, n = 17 and ATP, n = 21, respectively,
geometric means with 95% con¢dence intervals ; Fig. 3), and
respective maximal inward currents of 1126 þ 227 pA and
1070 þ 116 pA. Current-voltage relationships generated with
1 mM ATP reversed at 32.6 mV, and did not display marked
recti¢cation (data not shown). Repeated applications of 1 mM
ATP, for 1 s, produced currents that were successively larger,
such that the 20th application produced a current which was
261.1 þ 43.5% of the 1st application current (8th application
data shown in Fig. 4). Rise times and decay times for these
currents did not change signi¢cantly over the application pro-
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Fig. 2. Alignment of the predicted amino acid sequence of the mP2X7 subunit from NTW8 cells with the rat (1) and human (2) mP2X7 sub-
units. Overlined and marked as TM1 and TM2 indicate the predicted hydrophobic transmembrane segments. Amino acids shown for the hu-
man and rat mP2X7 subunits indicate the di¡erence in the sequence among the species orthologues. DNA sequence of the mP2X7 subunit has
been deposited in the EMBL database (accession number: AJ009823). Accession numbers for the rat and human mP2X7 orthologues at the
EMBL database are as follows: X95882 (rat) and Y9561 (human).
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tocol (Fig. 4). By analogy to the experiments in NTW8 micro-
glial cells (Fig. 4, [6]), this current augmentation is thought to
re£ect formation of the ‘large pore’ characteristic of the P2X7
receptor. Concentration-e¡ect curves (Fig. 3) generated fol-
lowing this pore-formation procedure yielded EC50 values
for BzATP and ATP of 90.4 (70.4^116.2) WM, n = 6, and
734.6 (707.2^762.8) WM, n = 15, respectively, which were not
signi¢cantly di¡erent from EC50 values derived before the
pore formation process (Table 1). Maximal inward currents
were 2150 þ 218 and 3866 þ 683 pA (BzATP and ATP, respec-
tively). Repeated applications of BzATP to cells expressing
either the rat or human P2X7 receptor revealed a di¡erent
phenotype (Fig. 4). The amplitude of currents evoked by suc-
cessive BzATP applications did not alter signi¢cantly over 8
applications, but the time taken for the inward currents to
return to baseline values progressively increased (Fig. 4).
This contrasts markedly to the phenotype of the recombinant
and NTW8 P2X7 receptors, where current amplitudes in-
creased, but deactivation time was unchanged.
3.3. YO-PRO-1 uptake
The uptake of this DNA binding dye, re£ecting large pore
activation, was studied in HEK-293 cells, expressing the
mouse P2X7, and in the native NTW8 cell line. For both
cell types, ATP and BzATP caused a concentration-dependent
uptake, with BzATP being a more potent agonist than ATP
(Fig. 5, Table 1). The increased potency of these agonists
compared to that seen in electrophysiological recordings is
attributable to di¡erences in bu¡er composition [10]. BzATP
was a more potent agonist at the rat and human recombinant
orthologues of P2X7 (see Table 1). The isoquinoline deriva-
tive, KN-62, inhibited BzATP-induced YO-PRO-1 in£ux in a
concentration-dependent manner, and showed similar potency
at both the recombinant mouse P2X7 receptor and at NTW8
cells (Table 1). By comparison, KN-62 was a more potent
antagonist at the human recombinant P2X7 receptor, and
was almost inactive at the rat recombinant P2X7 receptor
(Table 1). In addition, marked di¡erences in the sensitivity
to the non-selective P2 antagonist, PPADS, were observed
between the murine P2X7 receptors, and the human and rat
recombinant receptors (Table 1).
4. Discussion
We have isolated a cDNA encoding the murine P2X7 sub-
unit from the NTW8 mouse microglial cell line, which is
known to express P2X7 [6]. The operational characteristics
of recombinant homomeric channels formed by this P2X7
subunit, when expressed heterologously, are similar to those
observed in cells endogenously expressing mouse P2X7, but
di¡er markedly from other orthologues (rat and human) of
this receptor.
The potencies of the agonists, ATP and BzATP, in both
electrophysiological and YO-PRO-1 uptake studies, were sim-
ilar for the cloned mP2X7 receptor, and those observed for
the natively-expressing NTW8 cells [6] with less than ¢vefold
di¡erences in relative potencies for each agonist. As expected,
marked di¡erences in agonist potencies were observed be-
tween experiments performed using electrophysiological re-
cording and YO-PRO-1 uptake, which is attributable to the
absence of sodium and chloride ions in the latter experiments
[10]. In studies where current augmentation (thought to re£ect
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Fig. 3. Concentration-e¡ect curves to ATP (F and E) and BzATP
(b and a) in naive cells (closed symbols), and cells previously ex-
posed to multiple applications of 1 mM ATP (re£ecting the ‘pore
formed’ state of the receptor; open symbols). All data was obtained
from HEK293 cells expressing the mouse recombinant P2X7 recep-
tor, and are means þ S.E.M from at least 6 determinations.
Fig. 4. Representative traces of inward currents evoked by BzATP in cells expressing murine, rat and human P2X7 receptors. Numerical data
indicates the change in 95^5% deactivation time after 8 successive applications of BzATP (% increase), and the change in the inward current
amplitude over the same application protocol (% increase). Note the striking phenotypic di¡erences of current augmentation and deactivation
kinetics between murine, rat and human receptors. Numerical data is mean þ S.E.M. (dotted line) of at least 8 determinations.
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‘large pore’ formation) was examined, the NTW8 cells ap-
peared to undergo this process more rapidly, with a plateau
(of approximately 300% increase over the ¢rst current magni-
tude) for inward currents being attained after 8 applications
of 1 mM ATP. In the HEK-293 cells expressing the recombi-
nant receptor, a well-de¢ned plateau was not observed even
after 20 applications of 1 mM ATP, with the overall current
augmentation at this time being an increase of approximately
250% of the ¢rst application current, and approximately 75%
after 8 applications. The reasons for these modest quantitative
di¡erences may be due to receptor expression levels in the
respective cell lines, or perhaps re£ect a contribution of other
subunits to the channel assembly in the NTW8 cells. Indeed,
RT-PCR analysis has revealed the presence of additional P2X
subunits in this cell line (J. Simon, unpublished observations).
The operational behaviour of the heterologously expressed
mouse P2X7 receptor di¡ers considerably from the human
and rat orthologues in several ways. Thus, the growth in
current observed with repeated agonist applications (for
both the recombinant and natively-expressed receptor) con-
trasts markedly with the human and rat recombinant recep-
tors, where no such phenomenon is seen (see Fig. 4; [1,2]). In
addition, for both the rat and human receptors, alterations in
deactivation kinetics with multiple agonist applications are
observed, such that the time for the responses to return to
baseline became successively longer [1,7]. By contrast, for the
NTW8 and recombinant mouse receptors, this deactivation
time remained constant over multiple agonist applications.
This may be a re£ection of the way in which the large pore
is formed, and how rapidly pore closure occurs, with di¡ering
mechanisms between the rat and human and mouse ortho-
logues of this receptor.
There were also considerable di¡erences in ligand recogni-
tion between the murine P2X7 receptor and the other re-
combinant orthologues. In YO-PRO-1 uptake experiments,
BzATP was greater than 100-fold more potent at the rat re-
ceptor, and some 30-fold more potent at the human receptor.
There are also marked di¡erences in antagonist sensitivity.
Thus the potency of the P2X7 antagonist, KN-62 [13], is at
least 10-fold greater at the human recombinant P2X7 receptor
than at the recombinant mouse P2X7 receptor, and was al-
most ine¡ective at the recombinant rat P2X7 receptor. Fur-
thermore, PPADS, which was a potent antagonist at the hu-
man and rat recombinant receptors, was almost 100-fold less
potent at both the native and recombinant mouse P2X7 re-
ceptors. Similarly, calmidazolium, a potent antagonist at the
rat P2X7 receptor (IC50 of 13 nM [14]) produced little inhib-
ition of the mouse P2X7 receptor at a concentration of 1 WM
(I.P. Chessell, unpublished observations).
In summary, the cloning of the mouse P2X7 receptor will
allow further characterisation of this mechanistically intrigu-
ing receptor, and comparison of the various orthologues of
this receptor should aid the understanding of the mechanism
of channel to ‘large pore’ transition, characteristic of P2X7
receptors.
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Fig. 5. Concentration-e¡ect curves for agonist-induced YO-PRO-1
in£ux in NTW8 cells, and HEK293 cells expressing recombinant
murine P2X7 receptors (mP2X7) for BzATP (closed symbols) and
ATP (open symbols). Data is mean þ S.E.M. of at least 6 determina-
tions.
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